Kyverna Therapeutics, ElevateBio Announce Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy

Kyverna Therapeutics To Demonstrate Two Abstracts For Presentation At MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts selected for

Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions

Kyverna Therapeutics reports positive one-year clinical trial data for miv-cel in stiff person syndrome and myasthenia gravis.

Kyverna Therapeutics shares are trading higher after the company announced ne-year topline data from KYSA-8 and topline longer-term follow-up data from the Phase 2 portion of KYSA-6.

Kyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct

Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission